<DOC>
	<DOCNO>NCT01439893</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo parallel control , standard therapy base phase III clinical trial , evaluate efficacy recombinant human neuregulin-1 cardiac remodeling , well safety patient chronic heart failure .</brief_summary>
	<brief_title>Study Efficacy Cardiac Remodeling Recombinant Human Neuregulin-1 Stable Chronic Systolic Heart Failure Patients</brief_title>
	<detailed_description>RhNRG-1 ( recombinant human neuregulin-1 ) directly work cardiomyocytes restore normal structure function it.Both preclinical trial phase II clinical trail confirm rhNRG-1 effectively improve heart function , tolerate effective dosage group . The aim phase III trial confirm large population rhRNG-1 administration effectively improve cardiac remodel tolerated patient chronic heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>1 . Age 18 75 , sex . 2 . Left ventricular ejection fraction ( LVEF ) ≤40 % ( ECHO ) . 3 . NYNA functional class II~III . 4 . Definitely diagnosed chronic systolic heart failure ( include medical record , symptom physical sign ) clinical symptom steadily late 1 month . 5 . Receiving standard basic treatment heart failure , reach objective dosage high tolerated dosage least 1 month , dosage change least 1 month . 6 . Capable signing inform consent form . 1 . Patients atrial fibrillation . 2 . Patients pacemaker . 3 . Patient metallic implant . 4 . Patient Claustrophobia . 5 . Patients acute myocardial infarction , Hypertrophic cardiomyopathy , constrictive pericarditis , significant valvular pathological change congenital heart disease , severe pulmonary artery hypertension . 6 . Ischemic heart failure without recanalization recanalization recent six month . 7 . Cardiac surgery cerebrovascular accident within recent six month . 8 . Preparing heart transplantation receive CRT treatment . 9 . Serious hepatic renal dysfunction cause organic pathological change ( Cr＞2.0mg/dl , AST ALT 5 time normal upper limit ) . 10 . Patients need mechanical ventilation . 11 . Systolic blood pressure &lt; 90mmHg &gt; 160mmHg . 12 . Patients acute hemodynamic disorder decompensation last 1 month . 13 . Serious ventricular arrhythmia ( multimorphological premature ventricular contraction , frequent paroxysmal ventricular tachycardia ) . 14 . Serum potassium &lt; 3.2 mmol/L &gt; 5.5 mmol/L . 15 . Pregnant plan pregnant . 16 . Unmarried married procreated woman childbearing age . 17 . Subject life expectancy le 6 month assess investigator . 18 . Patients participate clinical trial recent three month . 19 . History malignancy suffer cancer , biopsy proven premalignant condition ( eg DICS cervical atypia ) . 20 . Evidence ( physical examination , CXR , ECHO test ) show active malignancy adenoidal hypertrophy neoplasm effect heart function endocrine system , eg pheochromocytoma hyperthyroidism . 21 . Judging investigator , patient could complete study adhere study requirement ( due management reason others ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic heart failure</keyword>
	<keyword>rhNRG-1</keyword>
	<keyword>Cardiac remodeling</keyword>
</DOC>